BioWorld MedTech

July 6, 2017

Edwards wins FDA approval for resilient heart valve device

Edwards Lifesciences Corp. received FDA approval for its Inspiris Resilia aortic valve. The Irvine, Calif.-based company said the valve is resistant to calcification, and leads the way for a new class of resilient heart valve devices. Read More

Fingerstick-free, disposable CGMs (and more) are on the way, but when?

NICE sees economics of Abbott's Freestyle Libre CGM as 'uncertain'

U.K. industry leaders encouraged by ministers' stance on post-Brexit drug/device regulation

U.S. stent makers view India price caps with suspicion

Other news to note

Financings

Daily M&A

Product briefs

Regulatory front

BioWorld MedTech's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 21, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...